Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (NYSE: BSX) is a global medical technology company whose news flow reflects activity across cardiovascular, neuromodulation, urology, endoscopy and other therapeutic areas. Company announcements frequently describe new agreements to acquire medical technology firms, clinical and regulatory milestones for key product platforms, and detailed quarterly financial results.
Recent news includes a definitive agreement to acquire Penumbra, Inc. in a cash and stock transaction. Penumbra has developed mechanical thrombectomy and neurovascular devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms, with products like the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems and peripheral embolization technologies. Boston Scientific has also announced an agreement to acquire Valencia Technologies Corporation, adding the eCoin implantable tibial nerve stimulation system for urge urinary incontinence, and an agreement to acquire Nalu Medical, Inc., developer of the Nalu Neurostimulation System for peripheral nerve stimulation in chronic pain.
In addition to acquisition news, Boston Scientific regularly issues earnings releases detailing net sales by business and region, growth rates on reported, operational and organic bases, and commentary on segment performance in MedSurg and Cardiovascular. These releases often highlight regulatory approvals, such as expanded labeling for the FARAPULSE Pulsed Field Ablation System or CE marks for devices like the WATCHMAN FLX Pro Left Atrial Appendage Closure Device, as well as clinical study results, including long-term data from deep brain stimulation trials.
Investors and observers following BSX news can also expect updates on investor conferences, investor day events, and governance matters disclosed through press releases and Form 8-K filings. This page aggregates such coverage, offering a centralized view of Boston Scientific’s strategic transactions, product developments, financial updates and corporate announcements over time.
Boston Scientific (NYSE: BSX) announced results from the ACURATE IDE clinical trial evaluating their ACURATE neo2™ Aortic Valve System for treating severe aortic stenosis. The trial's primary endpoint showed a 16.16% composite rate of all-cause mortality, stroke, or rehospitalization at one year in the ACURATE neo2 arm versus 9.53% in the control arm, failing to meet non-inferiority criteria. A post-hoc analysis revealed approximately 20% of valves were under-expanded, with data showing similar outcomes between properly expanded ACURATE neo2 valves and the control group. The company continues working with the FDA on regulatory approval strategy.
Boston Scientific (BSX) reported strong Q3 2024 results with net sales of $4.209 billion, representing a 19.4% increase year-over-year. The company achieved adjusted EPS of $0.63, exceeding guidance of $0.57-$0.59. Notable segment growth includes Cardiovascular at 25.0% and MedSurg at 10.3%. Regional performance showed U.S. sales growth of 23.5% and EMEA growth of 15.2%. The company received multiple regulatory approvals, including FDA approval for the FARAWAVE™ NAV Ablation Catheter and completed the acquisition of Silk Road Medical. For full-year 2024, BSX projects net sales growth of approximately 16.5% on a reported basis.
Boston Scientific (NYSE: BSX) has received FDA approval for the FARAWAVE™ NAV Ablation Catheter and FDA 510(k) clearance for the FARAVIEW™ Software. These technologies enhance the FARAPULSE™ Pulsed Field Ablation (PFA) System for treating paroxysmal atrial fibrillation (AF).
The FARAWAVE NAV Ablation Catheter adds magnetic navigation capabilities, allowing cardiac mapping and PFA therapy delivery in a single integrated catheter. The FARAVIEW Software provides visualization for cardiac ablation procedures, offering a dynamic view of catheter placement, shape, and rotation.
These advancements are designed to increase confidence in therapy delivery and simplify mapped workflows during PFA procedures. The FARAPULSE PFA System has been used to treat over 125,000 patients globally. Boston Scientific will immediately launch these new technologies in the U.S.
Boston Scientific (NYSE: BSX) has announced two upcoming events:
1. A conference call on October 23, 2024, at 8:00 a.m. ET to discuss third quarter 2024 financial results and business highlights. The call will be hosted by Mike Mahoney, chairman and CEO, and Dan Brennan, executive VP and CFO. Financial results will be released prior to the call.
2. A virtual investor event on October 30, 2024, from 4:00 – 5:00 p.m. ET following the Transcatheter Cardiovascular Therapeutics (TCT) symposium. This event will feature a cardiology business update and Q&A session with key executives from the company's cardiology division.
Live webcasts and replays for both events will be available on the Boston Scientific investor relations website.
Boston Scientific (NYSE: BSX) has received PMDA approval in Japan for the FARAPULSE™ Pulsed Field Ablation (PFA) System. This system is indicated for the isolation of pulmonary veins in treating paroxysmal atrial fibrillation (AF). Unlike traditional thermal ablation, the FARAPULSE PFA System uses non-thermal electrical fields, avoiding damage to surrounding structures.
The system has been used to treat over 125,000 patients globally and is now approved in more than 65 countries. AF affects over one million people in Japan and an estimated 38 million worldwide. Boston Scientific plans to launch the system in Japan following reimbursement approval and expects to initiate the OPTION-A clinical trial in early 2025 to study concomitant procedures using the FARAPULSE PFA System and the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device.
Boston Scientific (NYSE: BSX) has completed its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK) for $27.50 per share, representing an enterprise value of approximately $1.18 billion. This acquisition strengthens Boston Scientific's vascular technology solutions by integrating the innovative transcarotid artery revascularization (TCAR) platform for stroke prevention and carotid artery disease treatment.
The deal is expected to have a minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, becoming accretive thereafter. The impact on GAAP earnings may be less favorable due to amortization expenses and acquisition-related charges. This strategic move aims to expand the availability of TCAR to more physicians and patients through Boston Scientific's extensive commercial network.
Boston Scientific (NYSE: BSX) has received FDA approval to expand the indication for its INGEVITY™+ Pacing Leads to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA). This expansion allows for an alternative to traditional right ventricular pacing in treating symptomatic bradycardia. The LBBA pacing approach may promote greater ventricular synchrony and reduce long-term heart failure risk.
The approval was supported by data from the INSIGHT-LBBA study, involving approximately 400 patients. The INGEVITY+ Pacing Lead, which received initial FDA approval in 2019, features a stylet-driven design for precise positioning and continuous pacing and impedance monitoring capabilities.
Boston Scientific (NYSE: BSX) has obtained CE mark for its ACURATE Prime™ Aortic Valve System, a new transcatheter aortic valve replacement (TAVR) technology. This system expands treatment options for patients with larger anatomy and is designed for low, intermediate, and high-risk patients with severe aortic stenosis. Key features include:
- An enhanced frame for stable fit
- Redesigned deployment mechanism for accurate positioning
- Expanded treatment range (aortic annulus diameters 20.5-29 mm)
- Low pacemaker and paravalvular leak rates
- Strong hemodynamic performance
- Unrestricted coronary access for future procedures
The ACURATE Prime system will be launched in Europe in the coming weeks, building on the success of the ACURATE platform, which has been implanted in nearly 80,000 patients globally.
Boston Scientific (NYSE: BSX) has announced its participation in Wells Fargo's 2024 Healthcare Conference on September 4, 2024. The company's chairman and CEO, Mike Mahoney, along with Dr. Brad Sutton, chief medical officer of Atrial Fibrillation Solutions, will engage in a 35-minute Q&A session with the host analyst, starting at approximately 8:00 a.m. ET.
Investors and interested parties can access a live webcast of the session through the Boston Scientific investor relations website. A replay of the event will be made available about an hour after its conclusion, providing an opportunity for those unable to attend the live session to catch up on the discussion.
Boston Scientific (NYSE: BSX) has announced the election of David Habiger to its board of directors, effective immediately. Habiger brings over 30 years of business leadership experience and currently serves as president and CEO of J.D. Power. He has previously led several technology companies and is a director on the Chicago Federal Reserve Board. Boston Scientific's CEO, Mike Mahoney, welcomed Habiger, citing his experience in leading technology companies through pivotal growth periods as a valuable asset to the company's board.
Habiger's extensive background includes founding Silicon Media Partners and serving as CEO for companies like Textura, NDS Group, and Sonic Solutions. He holds an M.B.A. from The University of Chicago and a bachelor's degree in business administration from St. Norbert College. His appointment is expected to contribute to Boston Scientific's ongoing efforts to deliver transformative healthcare solutions.